Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Mannkind
Pharma
Mannkind wraps up phase 1 trial of inhaled lung infection asset
MannKind has wrapped up a phase 1 clinical trial of an inhaled formulation of clofazimine, teeing it up to talk to the FDA about advancing the asset.
Nick Paul Taylor
Sep 6, 2022 9:35am
United scores hard-earned FDA approval for inhaled Tyvaso
May 24, 2022 9:38am
MannKind inks $10M deal to buy Zealand’s insulin delivery tech
May 17, 2022 8:05am
RLS bags $10M to trial dry powder inhaled CBD in anxiety
Apr 12, 2022 8:00am
Lung safety review delays FDA decision on United's Tyvaso DPI
Mar 1, 2022 10:01am
MannKind raises $102M in sale-leaseback of manufacturing plant
Sep 30, 2021 9:40am
